- Company to Review Pipeline of Orphan Therapeutic Candidates,
Business Strategy and Recent Highlights -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2014--
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage
biopharmaceutical company developing novel therapeutics for orphan
patient populations with B-cell lymphomas and autoimmune diseases, today
announced that the Company will host a conference call and live audio
webcast with an accompanying slide presentation at 8:00 a.m. EDT on
Tuesday, May 13, 2014 to report its first quarter 2014 financial
results. The Company will also provide a detailed review of its pipeline
progress, business strategy, recent highlights and upcoming milestones.
In order to participate in the conference call, please dial
1-800-706-7741 (domestic) or 1-617-614-3471 (international) and provide
the access code 15389137. The live webcast and slides can be accessed
under “Investor Events” in the Investors section of the Company’s
website at www.iderapharma.com.
A replay of the call will be available at 1:30 p.m. EDT on May 13, 2014
until 11:59 p.m. EDT on May 20, 2014. To access the replay, please dial
1-888-286-8010 (domestic) or 1-617-801-6888 (international) and
reference the access code 88784725. The archived webcast will be
available for 30 days in the Investors section of Idera’s website at www.iderapharma.com.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company
developing a novel therapeutic approach for the treatment of genetically
defined forms of B-cell lymphoma and orphan autoimmune diseases. Idera’s
proprietary technology involves creating novel nucleic acid therapeutics
designed to inhibit over-activation of Toll-like Receptors (TLRs). In
addition to its TLR programs, Idera is developing gene silencing
oligonucleotides (GSOs) that it has created using its proprietary
technology to inhibit the production of disease-associated proteins by
targeting RNA.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
or
Stern
Investor Relations, Inc.
Sarah McCabe, 212-362-1200
sarah@sternir.com
